哮喘患者加用中药与类风湿关节炎风险降低相关:基于人群的回顾性队列研究
该回顾性队列研究利用全国医保数据,纳入33,963例新诊断哮喘且无类风湿关节炎(RA)的患者,经倾向评分匹配形成中药组与非中药组各13,440例。随访至2013年底,中药组RA累积发病率显著低于非中药组(1.92 vs 2.92/1000人年,调整HR=0.63,95%CI 0.54-0.75)。9种常用中药方剂或药材与较低RA风险相关。
要点
- 哮喘患者在接受常规治疗基础上加用中药,后续RA风险显著降低。
- 匹配后中药组RA发病率为1.92/1000人年,非中药组为2.92/1000人年。
- 小青龙汤、麻杏甘石汤等9种中药方剂或药材与较低RA风险相关。
核心结论
- 哮喘患者接受中药治疗联合常规治疗,与后续类风湿关节炎风险降低相关。
- 中药治疗可考虑整合入常规治疗以降低哮喘患者后续RA风险。
研究设计与样本
- 基于全国医保索赔数据的回顾性队列研究,纳入2000-2007年新诊断哮喘且无RA的20-80岁患者33,963例。
- 采用倾向评分匹配形成中药组和非中药组各13,440例,随访至2013年底。
- 使用Cox比例风险模型评估中药使用对RA风险的影响。
主要发现
- 中药组RA累积发病率显著低于非中药组。
- 随访期间中药组214例发生RA(1.92/1000人年),非中药组359例(2.92/1000人年)。
- 调整后HR=0.63(95%CI 0.54-0.75),提示中药使用与RA风险降低独立相关。
- 9种常用中药产品与较低RA风险相关:小青龙汤、麻杏甘石汤、定喘汤、辛夷清肺汤、贝母、桔梗、杏仁、大黄、三七。
关键数值与推荐
- 中药组RA发病率为1.92/1000人年,非中药组为2.92/1000人年。
- 调整后HR=0.63(95%CI 0.54-0.75)。
临床怎么用
- 对哮喘患者,在常规治疗基础上可考虑加用中药以潜在降低后续RA风险。
- 临床可关注小青龙汤、麻杏甘石汤、定喘汤、辛夷清肺汤及贝母、桔梗、杏仁、大黄、三七等中药在哮喘患者中的合理应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: Due to the shared pathogenesis of asthma and rheumatoid arthritis (RA), patients with asthma were found to have a higher risk of RA. While the benefits and safety of Chinese herbal medicine (CHM) for asthma have been reported, the scientific evidence regarding its effect on RA is limited. This longitudinal cohort study aimed to determine the relation between CHM use and RA risk in patients with asthma. Methods: Using the nationwide claims data, we enrolled 33,963 patients 20-80 years of age who were newly diagnosed with asthma and simultaneously free of RA between 2000 and 2007. From this sample, we utilized propensity score matching to create sets of participants as treatment and control groups, which comprised 13,440 CHM users and 13,440 non-CHM users. The incidence rate and hazard ratio (HR) for RA between the two groups were estimated at the end of 2013. A Cox proportional hazards model was constructed to examine the impact of the CHM use on the risk of RA. Results: The cumulative incidence of RA was substantially lower in the CHM user group. In the follow-up period, 214 patients in the CHM user group (1.92 per 1,000 person-years) and 359 patients in the non-CHM user group (2.92 per 1,000 person-years) developed RA (adjusted HR = 0.63, 95% confidence interval: 0.54-0.75). Of the commonly-prescribed formulae, nine CHM products were associated with a lower RA risk: Xiao-Qing-Long-Tang, Ma-Xing-Gan-Shi-Tang, Ding-Chuan-Tang, Xin-Yi-Qing-Fei-Tang, Bei Mu, Jie Geng, Xing Ren, Da Huang, and San Chi. Conclusion: This study found that patients with asthma who received CHM treatment, in addition to the conventional therapy, had a lower risk of RA. Use of CHM treatment may be integrated into conventional therapy to reduce subsequent RA risk among asthma patients.
引用
- Chang WC, Livneh H, Chen WJ, et al. Adding Chinese Herbal Medicine to Routine Care is Associated With a Lower Risk of Rheumatoid Arthritis Among Patients With Asthma: A Population-Based Retrospective Cohort Study. Front Pharmacol. 2022. PMID: 36059972. doi:10.3389/fphar.2022.895717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。